SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15

Oncogene

Volumn 31, Issue 37, 2012, Pages 4107-4116

  Tessema, M ^a   Yingling, C M ^a   Thomas, C L ^a   Klinge, D M ^a   Bernauer, A M ^a   Liu, Y ^a   Dacic, S ^b   Siegfried, J M ^b   Dahlberg, S E ^c   Schiller, J H ^d   Belinsky, S A ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

camptothecin; NSCLC; SULF 2; topotecan

Indexed keywords

CAMPTOTHECIN; CARBOPLATIN; DNA TOPOISOMERASE INHIBITOR; HEPARAN SULFATE 6 O ENDOSULFATASE; PACLITAXEL; SULFATASE; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; EPIGENETICS; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE INDUCTION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; ISG15 GENE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; CYTOKINES; DNA METHYLATION; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; SULFOTRANSFERASES; TOPOISOMERASE I INHIBITORS; TOPOTECAN; UBIQUITINS;

MUS MUSCULUS;

EID: 84859324880     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.577     Document Type: Article

References (35)

1. Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA, Orntoft TF. (2006). Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer 94: 1465-1471. (Pubitemid 43772282)
2. Bishop JR, Schuksz M, Esko JD. (2007). Heparan sulphate proteo-glycans fine-tune mammalian physiology. Nature 446: 1030-1037. (Pubitemid 46676065)
3. Desai SD, Haas AL, Wood LM, Tsai YC, Pestka S, Rubin EH et al. (2006). Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res 66: 921-928. (Pubitemid 43165959)
4. Desai SD, Wood LM, Tsai YC, Hsieh TS, Marks JR, Scott GL et al. (2008). ISG15 as a novel tumor biomarker for drug sensitivity. Mol Cancer Ther 7: 1430-1439.
5. Duan Z, Brakora KA, Seiden MV. (2004). Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 3: 833-838. (Pubitemid 39193765)
6. Gonzalez EE, Villanueva N, Fra J, Berros JP, Jimenez P, Luque M et al. (2010). Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study. Invest New Drugs 29: 1459-1464.
7. Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L et al. (2006). Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res 12: 7117-7125. (Pubitemid 44974512)
8. Johansson FK, Goransson H, Westermark B. (2005). Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice. Oncogene 24: 3896-3905. (Pubitemid 40896401)
9. Jones S, Thompson D, Barton J, Patton J, Shipley D, Greco FA et al. (2008). A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer. Clin Lung Cancer 9: 154-159. (Pubitemid 351880854)
10. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V et al. (2008). Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 99: 923-929.
11. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M et al. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792. (Pubitemid 40271173)
12. Lai JP, Oseini AM, Moser CD, Yu C, Elsawa SF, Hu C et al. (2010). The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation. Hepatology 52: 1680-1689.
13. Lai JP, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK et al. (2008). Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 47: 1211-1222. (Pubitemid 351547907)
14. Lemjabbar-Alaoui H, van Zante A, Singer MS, Xue Q, Wang YQ, Tsay D et al. (2010). Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. Oncogene 29: 635-646.
15. Lin CP, Ban Y, Lyu YL, Desai SD, Liu LF. (2008). A ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes. J Biol Chem 283: 21074-21083.
16. Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408. (Pubitemid 34164012)
17. Lortat-Jacob H, Kleinman HK, Grimaud JA. (1991). High-affinity binding of interferon-gamma to a basement membrane complex (matrigel). J Clin Invest 87: 878-883.
18. McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ. (2000). Topotecan has substantial antitumor activity as first-line
19. salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 18: 1062-1067.
20. Merry CL, Lyon M, Deakin JA, Hopwood JJ, Gallagher JT. (1999). Highly sensitive sequencing of the sulfated domains of heparan sulfate. J Biol Chem 274: 18455-18462.
21. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH et al. (2009). Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27: 4649-4655.
22. Morimoto-Tomita M, Uchimura K, Bistrup A, Lum DH, Egeblad M, Boudreau N et al. (2005). Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia 7: 1001-1010.
23. Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD. (2002). Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem 277: 49175-49185. (Pubitemid 36014346)
24. Nawroth R, van Zante A, Cervantes S, McManus M, Hebrok M, Rosen SD. (2007). Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS One 2: e392.
25. O'Brien M, Eckardt J, Ramlau R. (2007). Recent advances with topotecan in the treatment of lung cancer. Oncologist 12: 1194-1204. (Pubitemid 350106350)
26. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF et al. (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
27. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J et al. (2004). Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 64: 9027-9034. (Pubitemid 39665513)
28. Ramlau R, Gervais R, Krzakowski M, von Pawel J, Kaukel E, Abratt RP et al. (2006). Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol 24: 2800-2807. (Pubitemid 46630579)
29. Sugaya N, Habuchi H, Nagai N, Ashikari-Hada S, Kimata K. (2008). 6-O-sulfation of heparan sulfate differentially regulates various fibroblast growth factor-dependent signalings in culture. J Biol Chem 283: 10366-10376.
30. Tessema M, Klinge DM, Yingling CM, Do K, Van Neste L, Belinsky SA. (2010). Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene 29: 5159-5170.
31. Tessema M, Willink R, Do K, Yu YY, Yu W, Machida EO et al. (2008). Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. Cancer Res 68: 1707-1714. (Pubitemid 351416555)
32. Tessema M, Yu YY, Stidley CA, Machida EO, Schuebel KE, Baylin SB et al. (2009). Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. Carcinogenesis 30: 1132-1138.
33. Uchimura K, Morimoto-Tomita M, Bistrup A, Li J, Lyon M, Gallagher J et al. (2006). HSulf-2, an extracellular endoglucosa-mine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC Biochem 7: 2.
34. Weitz JJ, Marschke Jr RF, Sloan JA, Grill JP, Jett JR, Knost JA et al. (2000). A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung Cancer 28: 157-162. (Pubitemid 30136415)
35. White SC, Cheeseman S, Thatcher N, Anderson H, Carrington B, Hearn S et al. (2000). Phase II study of oral topotecan in advanced non-small cell lung cancer. Clin Cancer Res 6: 868-873. (Pubitemid 30159342)